Abstracts tagged "pulmonary"

Abstract Number: 0392 • ACR Convergence 2020
Prevalence and Survival of Systemic Sclerosis (SSc) and Associated Interstitial Lung Disease (ILD) in Ontario, Canada over 10 Years
Janet Pope¹, Kobina Quansah², Martin Kolb³, Jason Flavin⁴, Hassan Shazia⁵ and Soo Jin Seung⁵, ¹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ²Boehringer Ingelheim (Canada) Limited, Burlington, ON, Canada, ³McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamliton, ON, Canada, ⁴Boehringer Ingelheim, Corporate Headquarters, Burlington, ON, Canada, ⁵HOPE Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by skin thickening, vascular lesions and fibrotic changes in various organs, mainly the lungs, heart, intestinal…
Abstract Number: 1381 • ACR Convergence 2020
Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
Matthew Lammi¹, Kelly Chin², Nick H. Kim³, Vallerie McLaughlin⁴, Roham Zamanian⁵, Megan Flynn⁶, Sandrine Leroy⁷, Rose Ong⁷, Graham Wetherill⁷ and Richard Channick⁸, ¹Lousiana State University Health Sciences Center, New Orleans, LA, ²UT Southwestern Medical Center, Dallas, TX, ³University of California San Diego, La Jolla, CA, ⁴University of Michigan, Ann Arbor, MI, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA, ⁷Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ⁸University of California Los Angeles, Los Angeles
Background/Purpose: Patients with PAH-CTD have a worse prognosis than patients with most other PAH etiologies. The OPsumit® USers (OPUS) Registry and OPsumit® Historical USers (OrPHeUS)…
Abstract Number: 0398 • ACR Convergence 2020
Chest CT Ordering Practices at Expert Scleroderma Centers in the United States
Elana Bernstein¹, John VanBuren², Shervin Assassi³, Flavia Castelino⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech⁸, Emily Startup², Jessica Gordon⁹, Faye Hant¹⁰, Laura Hummers¹¹, Nora Sandorfi¹², Ami Shah¹³, Victoria Shanmugam¹⁴, Virginia Steen¹⁵ and Dinesh Khanna¹⁶, ¹Columbia University, New York, NY, ²University of Utah, Salt Lake City, UT, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Johns Hopkins Univerisity, Ellicott City, MD, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Johns Hopkins University School of Medicine, Ellicott City, MD, ¹⁴The George Washington University, Washington, DC, ¹⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Although pulmonary function tests (PFTs) are commonly used…
Abstract Number: 1430 • ACR Convergence 2020
The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis
Edouard Sayad¹, Tiphanie Vogel¹, David Moreno McNeill¹, Nahir Cortes-Santiago¹, David Spielberg¹, Kalyani Patel¹ and Manuel Silva Carmona¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX
Background/Purpose: Anca-associated vasculitis (AAV) is characterized by vascular inflammation in multiple organs. The diagnosis can be made clinically using a number of different criteria. The…
Abstract Number: 0461 • ACR Convergence 2020
High-Throughput Single-Cell Analysis Reveals Unique Lung Cellular Subsets in a Murine Model of Rheumatoid Arthritis-Inflammatory Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Amy Nelson¹, Meng Niu¹, Chittibabu Guda¹, James Eudy¹, Austin Barry¹, Debra Romberger¹, Michael Duryee¹, Bryant England¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA)-associated inflammatory lung disease is an extra-articular manifestation of RA associated with increased morbidity and mortality, whose precise molecular mechanisms remain undetermined.…
Abstract Number: 1522 • ACR Convergence 2020
Biomarkers of Hemodynamic Severity of Systemic-Sclerosis Associated Pulmonary Arterial Hypertension by Serum Proteome Analysis
Sebastien Sanges¹, Lisa Rice², Ly Tu³, Jean-Luc Cracowski⁴, David Montani⁵, Julio Mantero⁶, Camille Ternynck⁷, Guillemette Marot⁷, Eric Hachulla⁸, David Launay⁹, Marc Humbert⁵, Christophe Guignabert⁵ and Robert Lafyatis¹⁰, ¹Medecine Interne CHRU Lille, Lille, France, ²E5 Arthritis Center, Boston, MA, ³INSERM U1286, Le Kremlin Bicetre, France, ⁴Univ. Grenoble Alpes, INSERM, HP2, Grenoble, France, ⁵INSERM U999 "Pulmonary hypertension: Pathophysiology and Novel Therapies", Le Kremlin-Bicêtre, France, ⁶Boston University School of Medicine, E5 Arthritis Center, Boston, ⁷Univ. Lille, CHU Lille, ULR2694 – METRICS, Lille, France, ⁸Department of Internal Medicine, CHRU, Lille Cedex, France, ⁹Medecine Interne CHRU Lille, Lille Cedex, France, ¹⁰University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To investigate alterations in the serum proteome of patients with systemic sclerosis (SSc)-associated pulmonary hypertension (PAH), to identify proteins that correlated with hemodynamic severity…
Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Mark Nicolls¹, David Badesch ², Lorinda Chung ³, Robyn Domsic ⁴, Thomas Medsger ⁵, Ashley Pinckney ⁶, Lynette Keyes-Elstein ⁶, Carla D'Aveta ⁶, Meagan Spychala ⁶, R James White ⁷, Paul Hassoun ⁸, Fernando Torres ⁹, Jerry Molitor ¹⁰, Dinesh Khanna ¹¹, Holden Maeker ¹², Beverly Welch ¹³, Ellen Goldmuntz ¹⁴, Roham Zamanian ¹ and -- On Behalf of ASC01 Investigators ¹⁵, ¹Stanford University, Stanford, ²University of Colorado, Denver, ³Stanford University, Palo Alto, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, ⁶Rho Federal Systems, Durham, ⁷University of Rochester, Rochester, NY, ⁸Johns Hopkins School of Medicine, Baltimore, ⁹UT Southwestern, Dallas, ¹⁰University of Minnesota, University of Minnesota, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Stanford, Stanford, ¹³National Institute of Allergy and Infectious Diseases, NIH, Bethesda, ¹⁴NIAID, Washingto, DC, ¹⁵---, USA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].